These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 26729879)

  • 21. Dengue and Zika virus infections in children elicit cross-reactive protective and enhancing antibodies that persist long term.
    Katzelnick LC; Zambrana JV; Elizondo D; Collado D; Garcia N; Arguello S; Mercado JC; Miranda T; Ampie O; Mercado BL; Narvaez C; Gresh L; Binder RA; Ojeda S; Sanchez N; Plazaola M; Latta K; Schiller A; Coloma J; Carrillo FB; Narvaez F; Halloran ME; Gordon A; Kuan G; Balmaseda A; Harris E
    Sci Transl Med; 2021 Oct; 13(614):eabg9478. PubMed ID: 34613812
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody Epitopes Identified in Critical Regions of Dengue Virus Nonstructural 1 Protein in Mouse Vaccination and Natural Human Infections.
    Hertz T; Beatty PR; MacMillen Z; Killingbeck SS; Wang C; Harris E
    J Immunol; 2017 May; 198(10):4025-4035. PubMed ID: 28381638
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dominant cross-reactive B cell response during secondary acute dengue virus infection in humans.
    Zompi S; Montoya M; Pohl MO; Balmaseda A; Harris E
    PLoS Negl Trop Dis; 2012; 6(3):e1568. PubMed ID: 22448292
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases.
    Lai CY; Williams KL; Wu YC; Knight S; Balmaseda A; Harris E; Wang WK
    PLoS Negl Trop Dis; 2013; 7(9):e2451. PubMed ID: 24069496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune response to dengue virus and prospects for a vaccine.
    Murphy BR; Whitehead SS
    Annu Rev Immunol; 2011; 29():587-619. PubMed ID: 21219187
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Beyond Neutralizing Antibody Levels: The Epitope Specificity of Antibodies Induced by National Institutes of Health Monovalent Dengue Virus Vaccines.
    Swanstrom JA; Nivarthi UK; Patel B; Delacruz MJ; Yount B; Widman DG; Durbin AP; Whitehead SS; De Silva AM; Baric RS
    J Infect Dis; 2019 Jun; 220(2):219-227. PubMed ID: 30895307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preexisting neutralizing antibody responses distinguish clinically inapparent and apparent dengue virus infections in a Sri Lankan pediatric cohort.
    Corbett KS; Katzelnick L; Tissera H; Amerasinghe A; de Silva AD; de Silva AM
    J Infect Dis; 2015 Feb; 211(4):590-9. PubMed ID: 25336728
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Zika convalescent macaques display delayed induction of anamnestic cross-neutralizing antibody responses after dengue infection.
    Valiant WG; Huang YS; Vanlandingham DL; Higgs S; Lewis MG; Mattapallil JJ
    Emerg Microbes Infect; 2018 Jul; 7(1):130. PubMed ID: 30006514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A prospective nested case-control study of Dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model.
    Libraty DH; Acosta LP; Tallo V; Segubre-Mercado E; Bautista A; Potts JA; Jarman RG; Yoon IK; Gibbons RV; Brion JD; Capeding RZ
    PLoS Med; 2009 Oct; 6(10):e1000171. PubMed ID: 19859541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Delineating the serotype-specific neutralizing antibody response to a live attenuated tetravalent dengue vaccine.
    Gromowski GD; Henein S; Kannadka CB; Barvir DA; Thomas SJ; de Silva AM; Jarman RG
    Vaccine; 2018 Apr; 36(18):2403-2410. PubMed ID: 29602701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potent Plasmablast-Derived Antibodies Elicited by the National Institutes of Health Dengue Vaccine.
    Magnani DM; Silveira CGT; Ricciardi MJ; Gonzalez-Nieto L; Pedreño-Lopez N; Bailey VK; Gutman MJ; Maxwell HS; Domingues A; Costa PR; Ferrari L; Goulart R; Martins MA; Martinez-Navio JM; Fuchs SP; Kalil J; Timenetsky MDC; Wrammert J; Whitehead SS; Burton DR; Desrosiers RC; Kallas EG; Watkins DI
    J Virol; 2017 Nov; 91(22):. PubMed ID: 28878078
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
    Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
    Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary exposure to Zika virus is linked with increased risk of symptomatic dengue virus infection with serotypes 2, 3, and 4, but not 1.
    Zambrana JV; Hasund CM; Aogo RA; Bos S; Arguello S; Gonzalez K; Collado D; Miranda T; Kuan G; Gordon A; Balmaseda A; Katzelnick LC; Harris E
    Sci Transl Med; 2024 May; 16(749):eadn2199. PubMed ID: 38809964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preexisting Japanese encephalitis virus neutralizing antibodies and increased symptomatic dengue illness in a school-based cohort in Thailand.
    Anderson KB; Gibbons RV; Thomas SJ; Rothman AL; Nisalak A; Berkelman RL; Libraty DH; Endy TP
    PLoS Negl Trop Dis; 2011 Oct; 5(10):e1311. PubMed ID: 21991398
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The association of neutralizing antibodies with protection against symptomatic dengue virus infection varies by serotype, prior infection history, and assay condition.
    Bos S; Graber AL; Cardona-Ospina JA; Duarte EM; Zambrana JV; Ruíz Salinas JA; Mercado-Hernandez R; Singh T; Katzelnick LC; de Silva A; Kuan G; Balmaseda A; Harris E
    medRxiv; 2023 Oct; ():. PubMed ID: 37502957
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human monoclonal antibodies to neutralize all dengue virus serotypes using lymphocytes from patients at acute phase of the secondary infection.
    Setthapramote C; Sasaki T; Puiprom O; Limkittikul K; Pitaksajjakul P; Pipattanaboon C; Sasayama M; Leuangwutiwong P; Phumratanaprapin W; Chamnachanan S; Kusolsuk T; Jittmittraphap A; Asai A; Arias JF; Hirai I; Kuhara M; Okuno Y; Kurosu T; Ramasoota P; Ikuta K
    Biochem Biophys Res Commun; 2012 Jul; 423(4):867-72. PubMed ID: 22713454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct and indirect interactions in the recognition between a cross-neutralizing antibody and the four serotypes of dengue virus.
    Lisova O; Belkadi L; Bedouelle H
    J Mol Recognit; 2014 Apr; 27(4):205-14. PubMed ID: 24591178
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protection against symptomatic dengue infection by neutralizing antibodies varies by infection history and infecting serotype.
    Bos S; Graber AL; Cardona-Ospina JA; Duarte EM; Zambrana JV; Ruíz Salinas JA; Mercado-Hernandez R; Singh T; Katzelnick LC; de Silva A; Kuan G; Balmaseda A; Harris E
    Nat Commun; 2024 Jan; 15(1):382. PubMed ID: 38195666
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prior dengue virus infection and risk of Zika: A pediatric cohort in Nicaragua.
    Gordon A; Gresh L; Ojeda S; Katzelnick LC; Sanchez N; Mercado JC; Chowell G; Lopez B; Elizondo D; Coloma J; Burger-Calderon R; Kuan G; Balmaseda A; Harris E
    PLoS Med; 2019 Jan; 16(1):e1002726. PubMed ID: 30668565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of pre-existing cross-reactive antibodies on cyclic dengue outbreaks in the hyperendemic region of Bali, Indonesia.
    Balingit JC; Denis D; Suzuki R; Hayati RF; Ngwe Tun MM; Takamatsu Y; Masyeni S; Sasmono RT; Morita K
    Virus Res; 2024 Oct; 348():199445. PubMed ID: 39089369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.